Back HCV Treatment

HCV Treatment

Updated Hepatitis C Care and Treatment Guidelines Published in Hepatology

The latest updated U.S. recommendations for hepatitis C testing, management, and treatment, compiled by an expert panel of members of the American Association for the Study of Liver Diseases (AASLD) and partner organizations, have been published in the June 25 advance online edition of Hepatology, the AASLD's professional journal.

alt

Read more:

Adding Ribavirin to Harvoni for Hepatitis C Increases Side Effects But Not Efficacy

Combining sofosbuvir/ledipasvir (Harvoni) with ribavirin was associated with a greater likelihood of adverse events and laboratory abnormalities, but did not significantly increase the chances of sustained response for genotype 1 chronic hepatitis patients compared to sofosbuvir/ledipasvir alone, according to an analysis of the Phase 3 ION trials described in the July edition of Hepatology.

alt

Read more:

Merck Submits Grazoprevir/ Elbasvir for FDA Approval, BMS Gets Breakthrough Status for Daclatasvir

Merck has requested U.S. Food and Drug Administration (FDA) approval for its promising grazoprevir/elbasvir coformulation for people with hepatitis C virus genotypes 1, 4, or 6, the company recently announced. In related news, Bristol-Myers Squibb said that the FDA has granted Breakthrough Therapy status for daclatasvir plus sofosbuvir for people with advanced cirrhosis and liver transplant recipients.

alt

Read more:

Viekira Pak Regimen Cures 100% of Genotype 1b Hepatitis C Patients with Cirrhosis

All participants in the TURQUOISE-III trial, which enrolled HCV genotype 1b patients with compensated liver cirrhosis, achieved sustained virological response using AbbVie's Viekira Pak or "3D" regimen without ribavirin, according to a company announcement this week.

alt

Read more:

DDW 2015: Sofosbuvir/ Ledipasvir Cures Most Hepatitis C Patients with Cirrhosis

Sofosbuvir and ledipasvir -- the drugs in Harvoni -- are well-tolerated and highly effective for genotype 1 chronic hepatitis C patients with compensated cirrhosis, producing an overall cure rate of 96%, according to a pooled analysis of more than 500 participants in Phase 2 and 3 studies, according to a presentation at Digestive Disease Week 2015 this month in Washington, DC.

alt

Read more: